Patrick Wood
Stock Analyst at Morgan Stanley
(2.13)
# 2,864
Out of 5,182 analysts
121
Total ratings
41.67%
Success rate
-2.58%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $18.63 | +34.19% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $44.24 | +17.54% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $68.50 | +24.09% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $58.45 | +101.88% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $63.09 | +31.56% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $101.26 | +33.32% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $7.17 | +39.47% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $23.03 | +121.45% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $59.32 | +26.43% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $149.52 | +40.45% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $17.94 | -16.39% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $15.72 | +33.59% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $75.40 | +6.10% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $219.75 | +34.24% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $82.28 | -1.56% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $67.51 | +52.57% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $119.63 | -39.81% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $135.52 | +27.66% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $182.87 | +73.35% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $26.71 | +38.55% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.07 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $18.63
Upside: +34.19%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $44.24
Upside: +17.54%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $68.50
Upside: +24.09%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $58.45
Upside: +101.88%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $63.09
Upside: +31.56%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $101.26
Upside: +33.32%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.17
Upside: +39.47%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $23.03
Upside: +121.45%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $59.32
Upside: +26.43%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $149.52
Upside: +40.45%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $17.94
Upside: -16.39%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $15.72
Upside: +33.59%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $75.40
Upside: +6.10%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $219.75
Upside: +34.24%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $82.28
Upside: -1.56%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $67.51
Upside: +52.57%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $119.63
Upside: -39.81%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $135.52
Upside: +27.66%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $182.87
Upside: +73.35%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $26.71
Upside: +38.55%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.07
Upside: -